Advertisement

FDA Rules for Pregnancy and Lactation Labeling and Their Clinical Implications

  • Lauren M. OsborneEmail author
  • Nicole Leistikow
  • Renan Rocha
Chapter
  • 9 Downloads

Abstract

The new Food and Drug Administration (FDA) system for the use of drugs in pregnancy and lactation came into effect in 2015. The label content and format were reformulated, and any references to categories A, B, C, D, and X were removed and replaced by a summary of the perinatal risks of the substance, a discussion about the scientific data, and a synthesis of its relevance for medical treatment. The ultimate goal of the new standards is to facilitate the prescribing process by offering a consistent and well-structured set of information regarding the use of medications during pregnancy and lactation. The prior FDA category system had unintended effects on the perception and use of psychotropic medications in pregnancy and breastfeeding and contributed to a widespread overemphasis on the risks of these medications alongside a failure to appreciate the risks of untreated mental illness for women and babies. The clincial effect of the old categories in combination with stigma and lack of well designed research was likely the undertreatment of severe mental illness in pregnancy. The new FDA narrative summaries attempt to remedy these errors but require a high degree of medical knowledge about reproductive psychiatry and the evidence-based literature on the part of physcians and other providers. Specific medical training in the treatment of pregnant women with mental illness is a pressing need.

Keywords

Food and Drug Administration FDA Label Pregnancy Lactation Perinatal Drugs Stigma Safety Risk 

References

  1. 1.
    Freeman MP. Pregnancy and psychiatric disorders: inherent risks and treatment decisions. J Clin Psychiatry. 2013;74(4):373–4.  https://doi.org/10.4088/JCP.13f08356.CrossRefPubMedGoogle Scholar
  2. 2.
    Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy. 2014;34(4):389–95.  https://doi.org/10.1002/phar.1385.CrossRefGoogle Scholar
  3. 3.
    Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6(10):1221–86.  https://doi.org/10.3390/ph6101221.CrossRefGoogle Scholar
  4. 4.
    Pearlstein T. Use of psychotropic medication during pregnancy and the postpartum period. Women’s Health (Lond Engl). 2013;9(6):605–15.  https://doi.org/10.2217/whe.13.54.CrossRefGoogle Scholar
  5. 5.
    Ray S, Stowe ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014;28(1):71–83.  https://doi.org/10.1016/j.bpobgyn.2013.09.005.CrossRefPubMedGoogle Scholar
  6. 6.
    Koren G, Madjunkova S, Maltepe C. Bias against the null hypothesis: scaring pregnant women about drugs in pregnancy. Can Fam Physician. 2014;60:441–2. Available from: http://www.cfp.ca/content/cfp/60/5/441.full.pdf.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51.e1–8.  https://doi.org/10.1016/j.ajog.2011.02.029.CrossRefGoogle Scholar
  8. 8.
    Food and Drug Administration, HHS. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79(233):72063–103.Google Scholar
  9. 9.
    Tronnes JN, Lupattelli A, Nordeng H. Safety profile of medication used during pregnancy: results of a multinational european study. Pharmacoepidemiol Drug Saf. 2017;26(7):802–11.  https://doi.org/10.1002/pds.4213.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23(3):245–53.CrossRefGoogle Scholar
  11. 11.
    Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am J Obstet Gynecol. 2002;187(2):333–9.  https://doi.org/10.1067/mob.2002.125740.CrossRefGoogle Scholar
  12. 12.
    Cohen L. Limitations of pregnancy risk categories. https://womensmentalhealth.org/mcm_obgyn/limitations-of-pregnancy-risk-categories/. Updated 2001. Accessed 08/03, 2017.
  13. 13.
    Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Can Fam Physician. 2010;56(3):239–41.Google Scholar
  14. 14.
    Ward RK, Zamorski MA. Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician. 2002;66(4):629–36.PubMedGoogle Scholar
  15. 15.
    Scialli AR, Buelke-Sam JL, Chambers CD, et al. Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol. 2004;70(1):7–12.  https://doi.org/10.1002/bdra.10150.CrossRefPubMedGoogle Scholar
  16. 16.
    O’Connor E, Rossom RC, Henninger M, et al. FDA antidepressant drug labels for pregnant and postpartum women – screening for depression in adults: An updated systematic evidence review for the U.S. preventive services task force [internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. (Evidence Syntheses, No. 128.) Appendix A, FDA Antidepressant Drug Labels for Pregnant and Postpartum Women. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349032/. 2016:08/03/17.
  17. 17.
    Friedman JM. Report of the teratology society public affairs committee symposium on FDA classification of drugs. Teratology. 1993;48(1):5–6.  https://doi.org/10.1002/tera.1420480103.CrossRefPubMedGoogle Scholar
  18. 18.
    Czeizel AE. Recommendation to avoid all drugs during first trimester is unrealistic. BMJ. 1996;313(7054):424–5.CrossRefGoogle Scholar
  19. 19.
    Public Affairs Committee of the Teratology Society. Teratology public affairs committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defects Res A Clin Mol Teratol. 2007;79(9):627–30.  https://doi.org/10.1002/bdra.20389.CrossRefGoogle Scholar
  20. 20.
    Gendron MP, Martin B, Oraichi D, Berard A. Health care providers’ requests to teratogen information services on medication use during pregnancy and lactation. Eur J Clin Pharmacol. 2009;65(5):523–31.  https://doi.org/10.1007/s00228-008-0611-6.CrossRefPubMedGoogle Scholar
  21. 21.
    Einarson A, Park A, Koren G. How physicians perceive and utilize information from a teratogen information service: the motherisk program. BMC Med Educ. 2004;4:6.  https://doi.org/10.1186/1472-6920-4-6.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Einarson A, Portnoi G, Koren G. Update on motherisk updates. Seven years of questions and answers. Can Fam Physician. 2002;48:1301–4.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Ram D, Gowdappa B, Ashoka HG, Eiman N. Psychopharmacoteratophobia: excessive fear of malformation associated with prescribing psychotropic drugs during pregnancy: an indian perspective. Indian J Pharmacol. 2015;47(5):484–90.  https://doi.org/10.4103/0253-7613.165186.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cantilino A, Lorenzo L, Paula Jdos A, Einarson A. Use of psychotropic medications during pregnancy: perception of teratogenic risk among physicians in two latin american countries. Rev Bras Psiquiatr. 2014;36(2):106–10.CrossRefGoogle Scholar
  25. 25.
    Gils C, Pottegard A, Ennis ZN, Damkier P. Perception of drug teratogenicity among general practitioners and specialists in obstetrics/gynecology: a regional and national questionnaire-based survey. BMC Pregnancy Childbirth. 2016;16:226–016-1025-6.  https://doi.org/10.1186/s12884-016-1025-6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Osborne LM, Payne J. Antidepressants, pregnancy, and stigma: how we are failing mothers and babies. J Nerv Ment Dis. 2015;203(3):164–6.  https://doi.org/10.1097/NMD.0000000000000257.CrossRefPubMedGoogle Scholar
  27. 27.
    Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1–5.CrossRefGoogle Scholar
  28. 28.
    Urato AC. Are the SSRI antidepressants safe in pregnancy? Understanding the debate. Int J Risk Saf Med. 2015;27(2):93–9.  https://doi.org/10.3233/JRS-150646.CrossRefPubMedGoogle Scholar
  29. 29.
    Smyth C. Pregnant women warned over risks of antidepressants. Times Newspapers, London. 2012. p. 28.Google Scholar
  30. 30.
    Baird KL. The new NIH and FDA medical research policies: targeting gender, promoting justice. J Health Polit Policy Law. 1999;24(3):531–65.CrossRefGoogle Scholar
  31. 31.
    Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the american psychiatric association and the american college of obstetricians and gynecologists. Obstet Gynecol. 2009;114(3):703–13.  https://doi.org/10.1097/AOG.0b013e3181ba0632.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014;10:369–92.  https://doi.org/10.1146/annurev-clinpsy-032813-153626.CrossRefPubMedGoogle Scholar
  33. 33.
    Wang SS. Therapy preferred to drugs for depression in pregnancy. Wall Street J – Eastern Edition. 2009;254(44):A5.Google Scholar
  34. 34.
    Wilson C. Pregnancy dilemma: antidepressants and depression may both harm a fetus. New Sci. 2009;204(2731):12.CrossRefGoogle Scholar
  35. 35.
  36. 36.
    Gibb G. With paxil an FDA category D, will other antidepressants follow? https://www.lawyersandsettlements.com/articles/paxil-heart-defects-newborn/paxil-side-effects-lawsuit-birth-defects-32-15966.html. Accessed 08/09, 2017.
  37. 37.
    Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.CrossRefGoogle Scholar
  38. 38.
    Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24; quiz 1923.CrossRefGoogle Scholar
  39. 39.
    Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160(5 Pt 1):1107–11.CrossRefGoogle Scholar
  40. 40.
    Ross LE, Grigoriadis S. Selected pregnancy and delivery outcomes after exposure to antidepressant medication. JAMA Psychiat. 2014;71(6):716–7.  https://doi.org/10.1001/jamapsychiatry.2014.59.CrossRefGoogle Scholar
  41. 41.
    Rotem-Kohavi N, Oberlander TF. Variations in neurodevelopmental outcomes in children with prenatal SSRI antidepressant exposure. Birth Defects Res. 2017;109(12):909–23.  https://doi.org/10.1002/bdr2.1076.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Grace SL, Evindar A, Stewart DE. The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch Womens Ment Health. 2003;6(4):263–74.  https://doi.org/10.1007/s00737-003-0024-6.CrossRefPubMedGoogle Scholar
  43. 43.
    O’Connor TG, Heron J, Golding J, Glover V, ALSPAC Study Team. Maternal antenatal anxiety and behavioural/emotional problems in children: a test of a programming hypothesis. J Child Psychol Psychiatry. 2003;44(7):1025–36.CrossRefGoogle Scholar
  44. 44.
    O’Connor TG, Heron J, Golding J, Beveridge M, Glover V. Maternal antenatal anxiety and children’s behavioural/emotional problems at 4 years. Report from the avon longitudinal study of parents and children. Br J Psychiatry. 2002;180:502–8.CrossRefGoogle Scholar
  45. 45.
    Koren G. The way women perceive teratogenic risk. Can J Clin Pharmacol. 2007;14(1):e10–6.PubMedGoogle Scholar
  46. 46.
    Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health. 2005;8(4):214–20.  https://doi.org/10.1007/s00737-005-0094-8.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Dolman C, Jones IR, Howard LM. Women with bipolar disorder and pregnancy: factors influencing their decision-making. BJPsych Open. 2016;2(5):294–300.  https://doi.org/10.1192/bjpo.bp.116.003079.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Walton GD, Ross LE, Stewart DE, Grigoriadis S, Dennis CL, Vigod S. Decisional conflict among women considering antidepressant medication use in pregnancy. Arch Womens Ment Health. 2014;17(6):493–501.  https://doi.org/10.1007/s00737-014-0448-1.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci. 2001;26(1):44–8.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Stahl SM. Stahl’s essential psychopharmacology: Neuroscientific basis and practical application. 6th ed. Cambridge: Cambridge University Press; 2017. p. 608.Google Scholar
  51. 51.
    Langan R, Goodbred AJ. Identification and management of peripartum depression. Am Fam Physician. 2016;93(10):852–8.Google Scholar
  52. 52.
    Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.  https://doi.org/10.1136/bmj.f6932.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    CDC. Treating for two. https://www.cdc.gov/pregnancy/meds/treatingfortwo/research.html. Accessed 20 Nov 2017.
  54. 54.
    Solomon A. The secret sadness of pregnancy with depression. The New York times, New York magazine. 2015.Google Scholar
  55. 55.
    ACGME program requirements for graduate medical education in psychiatry. https://www.acgme.org/Portals/0/PFAssets/ProgramRequirements/400_psychiatry_2016.pdf. Accessed 06 June 2017.
  56. 56.
    Osborne LM, MacLean JV, Barzilay EM, Meltzer-Brody S, Miller L, Yang SN. Reproductive psychiatry residency training: a survey of psychiatric residency program directors. Acad Psychiatry. 2017;  https://doi.org/10.1007/s40596-017-0672-x.CrossRefGoogle Scholar
  57. 57.
    Nagle-Yang S, Miller L, Osborne LM. Reproductive psychiatry fellowship training: identification and characterization of current programs. Acad Psychiatry. 2017;  https://doi.org/10.1007/s40596-017-0690-8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Lauren M. Osborne
    • 1
    Email author
  • Nicole Leistikow
    • 2
  • Renan Rocha
    • 3
  1. 1.Women’s Mood Disorders Center, The Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Division of Consultation-Liaison, Department of PsychiatryUniversity of Maryland School of MedicineBaltimoreUSA
  3. 3.Private Practice, São Lucas Medical Institute CriciúmaSanta CatarinaBrazil

Personalised recommendations